[1]
Barker DJ. The fetal and infant origins of adult disease. BMJ 1990; 301(6761): 1111.
[http://dx.doi.org/10.1136/bmj.301.6761.1111] [PMID: 2252919]
[http://dx.doi.org/10.1136/bmj.301.6761.1111] [PMID: 2252919]
[2]
Barker DJ. The intrauterine origins of cardiovascular and obstructive lung disease in adult life. The Marc Daniels Lecture 1990. J R Coll Physicians Lond 1991; 25(2): 129-33.
[PMID: 2066923]
[PMID: 2066923]
[3]
Barker DJ. Fetal origins of coronary heart disease. Heart 1993; 69(3): 195-6.
[http://dx.doi.org/10.1136/hrt.69.3.195] [PMID: 8461215]
[http://dx.doi.org/10.1136/hrt.69.3.195] [PMID: 8461215]
[4]
Triantafyllidou P, Papadopoulou A, Thymara E, et al. Aortic intima media thickness is increased in neonates of mothers with gestational diabetes mellitus: The role of thioredoxin-interacting protein as a marker of oxidative stress. Curr Vasc Pharmacol 2023.
[http://dx.doi.org/10.2174/1570161121666230727150854]
[http://dx.doi.org/10.2174/1570161121666230727150854]
[5]
West HW, Juonala M, Gall SL, et al. Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation 2015; 131(14): 1239-46.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013485] [PMID: 25802269]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013485] [PMID: 25802269]
[6]
Bogdarina I, Welham S, King PJ, Burns SP, Clark AJL. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res 2007; 100(4): 520-6.
[http://dx.doi.org/10.1161/01.RES.0000258855.60637.58] [PMID: 17255528]
[http://dx.doi.org/10.1161/01.RES.0000258855.60637.58] [PMID: 17255528]
[7]
Nuyt AM, Alexander BT. Developmental programming and hypertension. Curr Opin Nephrol Hypertens 2009; 18(2): 144-52.
[http://dx.doi.org/10.1097/MNH.0b013e328326092c] [PMID: 19434052]
[http://dx.doi.org/10.1097/MNH.0b013e328326092c] [PMID: 19434052]
[8]
Goyal R, Goyal D, Leitzke A, Gheorghe CP, Longo LD. Brain renin-angiotensin system: Fetal epigenetic programming by maternal protein restriction during pregnancy. Reprod Sci 2010; 17(3): 227-38.
[http://dx.doi.org/10.1177/1933719109351935] [PMID: 19923380]
[http://dx.doi.org/10.1177/1933719109351935] [PMID: 19923380]
[9]
Paraskevas KI, Briana DD, Malamitsi-Puchner A, Mikhailidis DP. Fetal/infant origins of adult vascular disease. Curr Vasc Pharmacol 2020; 18(4): 418-20.
[http://dx.doi.org/10.2174/1570161118999200304123040] [PMID: 32129165]
[http://dx.doi.org/10.2174/1570161118999200304123040] [PMID: 32129165]
[10]
Vekic J, Zeljkovic A, Mihajlovic M, et al. The prospect of genomic, transcriptomic, epigenetic and metabolomic biomarkers for the personalized prevention of type 2 diabetes and cardiovascular diseases. Curr Vasc Pharmacol 2023; 21(3): 185-96.
[http://dx.doi.org/10.2174/1570161121666230510141338] [PMID: 37165508]
[http://dx.doi.org/10.2174/1570161121666230510141338] [PMID: 37165508]
[11]
Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the european society of cardiology working group on peripheral circulation. Atherosclerosis 2015; 241(2): 507-32.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.007] [PMID: 26117398]
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.007] [PMID: 26117398]
[12]
Espinoza C, Fuenzalida B, Leiva A. Increased fetal cardiovascular disease risk: Potential synergy between gestational diabetes mellitus and maternal hypercholesterolemia. Curr Vasc Pharmacol 2021; 19(6): 601-23.
[http://dx.doi.org/10.2174/1570161119666210423085407] [PMID: 33902412]
[http://dx.doi.org/10.2174/1570161119666210423085407] [PMID: 33902412]
[13]
Sobrevia L, Aiello EA, Contreras P. Mechanisms of endothelial dysfunction and cardiovascular system adaptation. Curr Vasc Pharmacol 2022; 20(3): 201-4.
[http://dx.doi.org/10.2174/157016112003220825112123] [PMID: 36165539]
[http://dx.doi.org/10.2174/157016112003220825112123] [PMID: 36165539]
[14]
Briana DD, Malamitsi-Puchner A. Effect of gestational diabetes mellitus and hypercholesterolemia on fetal cardiovascular disease risk: The role of epigenetics. Curr Vasc Pharmacol 2022; 20(4): 379-80.
[http://dx.doi.org/10.2174/1570161120666220804090725] [PMID: 36123823]
[http://dx.doi.org/10.2174/1570161120666220804090725] [PMID: 36123823]
[15]
Leiva A, Espinoza C, Fuenzalida B. Epigenetic changes as a possible mechanism leading to increased fetal cardiovascular disease risk in pregnancies with gestational diabetes mellitus and/or maternal hypercholesterolemia. Curr Vasc Pharmacol 2022; 20(4): 381.
[http://dx.doi.org/10.2174/1570161120666220314090700] [PMID: 35289249]
[http://dx.doi.org/10.2174/1570161120666220314090700] [PMID: 35289249]